| 产品编号 | bs-15466R |
| 英文名称 | Rabbit Anti-ERVFRD-1 antibody |
| 中文名称 | ERVFRD-1抗体 |
| 别 名 | SYCY2_HUMAN; EFRD1_HUMAN; Endogenous retrovirus group FRD member 1; Envelope polyprotein; HERV-FRD; HERV-FRD_6p24.1 provirus ancestral Env polyprotein; TM; SU; ERVFRD-1; ERVFRDE1; UNQ6191/PRO20218; |
 |
Specific References (2) | bs-15466R has been referenced in 2 publications.
[IF=5.168] Díaz-Carballo et al. Cytotoxic stress induces transfer of mitochondria-associated human endogenous retroviral RNA and proteins between cancer cells. (2017) Oncotarget. 8:95945-95964 other ; Human.
[IF=4.43] Díaz-Carballo, David, et al. "Therapeutic potential of antiviral drugs targeting chemorefractory colorectal adenocarcinoma cells overexpressing endogenous retroviral elements." Journal of Experimental & Clinical Cancer Research 34.1 (2015): 81. WB ; Human.
|
| 研究领域 | 细菌及病毒 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human |
| 产品应用 | WB=1:500-2000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 21/37/58kDa |
| 细胞定位 | 细胞膜 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human HERV-FRD : 331-430/538 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
Retroviral envelope proteins mediate receptor recognition and membrane fusion during early infection. Endogenous envelope proteins may have kept, lost or modified their original function during evolution. This endogenous envelope protein has retained its original fusogenic properties. Can make pseudotypes with MLV, HIV-1 or SIV-1 virions and confer infectivity. SU mediates receptor recognition (By similarity). TM anchors the envelope heterodimer to the viral membrane through one transmembrane domain. The other hydrophobic domain, called fusion peptide, mediates fusion of the viral membrane with the target cell membrane (By similarity). Subunit: The surface (SU) and transmembrane (TM) proteins form a heterodimer. SU and TM are attached by noncovalent interactions or by a labile interchain disulfide bond (By similarity). Subcellular Location: Virion. Transmembrane protein: Cell membrane; Single-pass membrane protein (Potential). Tissue Specificity: Expressed at higher level in placenta. Expressed at lower level in adrenal, bone marrow, brain, breast, colon, kidney, lung, ovary, peripheral blood lymphocytes, prostate, skin, spleen, testis, thymus, thyroid, trachea. Post-translational modifications: Specific enzymatic cleavages in vivo yield the mature SU and TM proteins (By similarity). The CXXC motif is highly conserved across a broad range of retroviral envelope proteins. It is thought to participate in the formation of a labile disulfide bond possibly with the CX6CC motif present in the transmembrane protein. Isomerization of the intersubunit disulfide bond to an SU intrachain disulfide bond is thought to occur upon receptor recognition in order to allow membrane fusion (By similarity). Similarity: Belongs to the gamma type-C retroviral envelope protein family. HERV class-I FRD env subfamily. SWISS: P60508 Gene ID: 405754 Database links:
SwissProt: P60508 Human |
| 产品图片 |
Sample:
Lane 1: Human HeLa cell lysates
Lane 2: Human HepG2 cell lysates
Lane 3: Human A431 cell lysates
Lane 4: Human SH-SY5Y cell lysates
Lane 5: Human A549 cell lysates
Lane 6: Human K562 cell lysates
Lane 7: Human 293T cell lysates
Primary: Anti-ERVFRD-1 (bs-15466R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 21/37/58 kDa
Observed band size: 60 kDa
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
